*Streptococcus pneumoniae* is a common respiratory pathogen that is the leading cause of community-acquired pneumonia ([@R1]). Although β-lactam antibiotics have long been used for the treatment of respiratory diseases, the increasing prevalence of antibiotic-resistant *S. pneumoniae* strains has hampered treatment in recent decades ([@R2],[@R3]). Resistance to fluoroquinolones has emerged in *S. pneumoniae* and is caused by mutations within short DNA sequences of *gyrA* and *parC* genes that encode the type II topoisomerase subunits known as quinolone-resistance determining regions (QRDRs) ([@R1]). Previous studies have shown that most of the *S. pneumoniae* strains with reduced susceptibility to the fluoroquinolone levofloxacin exhibit a multidrug-resistant (MDR) phenotype ([@R2],[@R4]). Levofloxacin resistance was closely associated with epidemic MDR clones ([@R3]). Although fluoroquinolone resistance rates remain low in *S. pneumoniae* in most countries, some extensively drug-resistant (XDR) *S. pneumoniae* isolates have emerged; this resistance is defined as nonsusceptibility to [\>]{.ul}1 agent in all but [\<]{.ul}2 antimicrobial categories ([@R2],[@R4]). We examined *S. pnemoniae* isolates from patients in South Korea to determine antimicrobial resistance. We found novel sequence types (STs) of MDR serotype 11A *S. pneumoniae* that exhibit resistance to second-line antibiotics such as levofloxacin, ceftriaxone, and meropenem.

The Study
=========

During January 2009--December 2014, we isolated 608 *S. pneumoniae* clinical strains at a 698-bed, university-affiliated hospital in South Korea. We determined MICs by using the broth microdilution method according to Clinical and Laboratory Standards Institute guidelines ([@R5]). We performed antimicrobial resistance tests for levofloxacin, ofloxacin, ciprofloxacin, penicillin, amoxicillin, ceftriaxone, meropenem, erythromycin, clindamycin, vancomycin, linezolid, tetracycline, and tigecycline. We used *S. pneumoniae* ATCC 49619 as a control strain. We defined MDR as resistance or intermediate resistance to [\>]{.ul}3 antimicrobial agents.

We determined serotypes by using the multiplex PCR assay recommended by the Centers for Disease Control and Prevention (<http://www.cdc.gov/ncidod/biotech/strep/pcr.htm>). Reactions also included an internal positive control targeting all known pneumococcal *cpsA* regions ([@R6]). We sequenced QRDRs of the *gyrA*, *gyrB*, *parC*, and *parE* genes in each isolate ([@R7]). We performed multilocus sequence typing to investigate the genetic backgrounds of fluoroquinolone-resistant pneumococci ([@R8]) and assigned allele numbers and STs by using the PubMLST database (<http://pubmlst.org/spneumoniae>).

Of the 608 clinical *S. pneumoniae* isolates, 16 (2.6%) were levofloxacin resistant (MIC [\>]{.ul}8 μg/mL). We collected 1 resistant isolate in 2009, 3 in 2012, 5 in 2013, and 7 in 2014. Thirteen isolates were from sputum, and 3 isolates were from bronchial lavage. The mean age of patients was 71 years; 14 were male, and 2 were female.

Serotype 11A (n = 9) was most common among the levofloxacin-resistant isolates, followed by serotypes 13 (n = 2), 19F (n = 2), 23F (n = 2), and 6B (n = 1) ([Table 1](#T1){ref-type="table"}). The most common STs were ST9875 (n = 5), ST8279 (n = 3), and ST9876 (n = 3), which together accounted for 11 of the 16 levofloxacin-resistant isolates. Nine isolates of ST9875, ST9876, and ST10300 were novel STs and had not been identified before this study.

###### Select characteristics of 16 levofloxacin-resistant *Streptococcus pneumoniae* clinical isolates identified from patients at a hospital in South Korea, 2009--2014\*†

  Strain    Age, y/sex of patient   Specimen type   Respiratory disorders   Underlying disorders   Serotype   Sequence type
  --------- ----------------------- --------------- ----------------------- ---------------------- ---------- ---------------
  HM-669    70/M                    Sputum          Pneumonia               CVA                    11A        9875‡
  HM-683    77/M                    Sputum          Pneumonia               COPD                   6B         3173
  HM-688    81/M                    Sputum          Pneumonia               Cardiac infarction     23F        9876‡
  HM-730    77/M                    Sputum          Dyspnea with fever      Cervical pain          13         189
  HM-762    76/F                    Sputum          Pneumonia               Lung cancer            13         8279
  HM-781    70/M                    Sputum          Pneumonia               CVA                    23F        6721
  HM-787    35/M                    Sputum          Pneumonia               CVA                    11A        9875‡
  HM-809    58/M                    Sputum          Pneumonia               CVA                    11A        9875‡
  HM-854    77/M                    BL              Pneumonia               Lung cancer            11A        99
  HM-878    67/M                    BL              Pneumonia               ALS                    11A        8279
  HM-953    82/M                    Sputum          Pneumonia               COPD                   11A        9875‡
  HM-970    68/M                    Sputum          Dyspnea with fever      Bronchiectasis         19F        9876‡
  HM-1017   85/M                    BL              Dyspnea                 Lung cancer            11A        8279
  HM-1050   62/M                    Sputum          Postop atelectasis      CVA                    19F        9876‡
  HM-1055   89/F                    Sputum          Pneumonia               CVA                    11A        10300‡

\*ALS, amyotrophic lateral sclerosis; BL, bronchial lavage; COPD, chronic obstructive pulmonary disorder; CVA, cerebrovascular accident. †Among the 16 isolates, 1 (HM-646) was collected in 2009; 3 (HM-669, HM-683, and HM-688) in 2012; 5 (HM-730, HM-762, HM-781, HM-787, and HM-809) in 2013; and 7 (HM-854, HM-878, HM-953, HM-970, HM-1017, HM-1050, and HM-1055) in 2014. ‡Novel sequence type found in our study.

All 16 levofloxacin-resistant isolates contained at least 2 amino acid alterations in the QRDRs of the *gyrA, parC*, and *parE* genes. Four QRDR mutations occurred with high frequency: Ser81Phe in *gyrA* was present in all 16 isolates; Ser79Phe and Lys137Asn in *parC* were present in 14 and 11 isolates, respectively; and Ile460Val in *parE* was found in 15 isolates. However, Lys137Asn in *parC* and Asp435Val and Ile460Val in *parE* are mutations not involved in resistance, according to previous reports ([@R9],[@R10]). Isolate HM-854, which was penicillin susceptible, had Ser81Phe in *gyrA* and Asp79Asn in *parC* mutations. All isolates had [\>]{.ul}1 mutation in *parC*. The 2 isolates without the Ser79Phe mutation in *parC* instead carried Asp83Gly or Asp83Asn. The 4 isolates without the Lys137Asn mutation in *parC* instead carried the Asn91Asp mutation. Isolate HM-1017 (serotype 11A, ST-8279) had 7 QRDR mutations and exhibited the highest resistance against all antimicrobial agents, including levofloxacin (MIC 64 μg/mL). ST-8279 was associated with 2 different serotypes, 11A (n = 2) and 13 (n = 1). The 3 isolates of novel ST-9876 had the same QRDR amino acid changes but had different serotypes, 19F (n = 2) and 23F (n = 1).

The 16 levofloxacin-resistant isolates were also resistant to ofloxacin (MIC [\>]{.ul}8 μg/mL) and ciprofloxacin (MIC [\>]{.ul}8 μg/mL) ([Table 2](#T2){ref-type="table"}). All isolates except 3 had MICs [\>]{.ul}16 μg/mL against amoxicillin and ceftriaxone. Fourteen isolates were meropenem-resistant (MIC [\>]{.ul}1 μg/mL); all these isolates were susceptible to vancomycin and linezolid. Only 3 STs (ST-99, ST-189, and ST-3173) exhibited the lowest levofloxacin MIC (8 μg/mL); all these isolates were susceptible to amoxicillin (MIC [\<]{.ul}2 μg/mL).

###### Antimicrobial susceptibilities of 16 levofloxacin-resistant *Streptococcus pneumoniae* clinical isolates identified from patients at a hospital in South Korea, 2009--2014\*

  Strain    MIC, μg/mL (resistance)                                                                                                                       
  --------- ------------------------- --------- ----- ---------- ---------- ---------- ------------- ---------- ---------- --------- --------- ---------- -------
  HM-669    16 (R)                    32 (R)    32    \>16 (R)   \>16 (R)   \>16 (R)   8 (R)         \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     \>16 (R)   0.03
  HM-683    8 (R)                     16 (R)    16    4 (I)      2 (S)      2 (I)      1 (R)         \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     \>16 (R)   0.03
  HM-688    16 (R)                    32 (R)    32    \>16 (R)   \>16 (R)   \>16 (R)   8 (R)         \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     \>16 (R)   0.03
  HM-730    8 (R)                     16 (R)    8     4 (I)      2 (S)      2 (I)      0.5 (I)       \>16 (R)   \>16 (R)   0.5 (S)   0.5 (S)   \>16 (R)   0.03
  HM-762    32 (R)                    64 (R)    32    \>16 (R)   \>16 (R)   \>16 (R)   16 (R)        \>16 (R)   \>16 (R)   0.5 (S)   0.5 (S)   \>16 (R)   0.015
  HM-781    16 (R)                    32 (R)    16    16 (R)     16 (R)     \>16 (R)   8 (R)         \>16 (R)   \>16 (R)   0.5 (S)   0.5 (S)   16 (R)     0.03
  HM-787    16 (R)                    32 (R)    64    16 (R)     16 (R)     \>16 (R)   8 (R)         \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     \>16 (R)   0.03
  HM-809    16 (R)                    32 (R)    64    16 (R)     \>16 (R)   \>16 (R)   4 (R)         \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     \>16 (R)   0.03
  HM-854    8 (R)                     16 (R)    16    0.06 (S)   0.06 (S)   0.5 (S)    \<0.015 (S)   8 (R)      0.06 (S)   0.5 (S)   1 (S)     \>16 (R)   0.03
  HM-878    16 (R)                    32 (R)    32    16 (R)     \>16 (R)   \>16 (R)   8 (R)         \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     4 (R)      0.03
  HM-953    16 (R)                    32 (R)    64    \>16 (R)   \>16 (R)   \>16 (R)   16 (R)        \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     \>16 (R)   0.03
  HM-970    32 (R)                    64 (R)    32    \>16 (R)   \>16 (R)   \>16 (R)   16 (R)        \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     \>16 (R)   0.03
  HM-1017   64 (R)                    128 (R)   64    \>16 (R)   \>16 (R)   \>16 (R)   16 (R)        \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     \>16 (R)   0.03
  HM-1050   32 (R)                    64 (R)    64    \>16 (R)   \>16 (R)   \>16 (R)   16 (R)        \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     0.5 (S)    0.03
  HM-1055   16 (R)                    32 (R)    128   \>16 (R)   \>16 (R)   \>16 (R)   16 (R)        \>16 (R)   \>16 (R)   0.5 (S)   1 (S)     \>16 (R)   0.03

\*AMX, amoxicillin; CIP, ciprofloxacin; CLI, clindamycin; CRO, ceftriaxone; ERY, erythromycin; I, intermediate; LEV, levofloxacin; LZD, linezolid; MER, meropenem; OFL, ofloxacin; PEN, penicillin; R, resistant; S, susceptible; TET, tetracycline; TIG, tigecycline; VAN, vancomycin. †No susceptibility breakpoints are established for ciprofloxacin and tigecycline.

Most of the 16 isolates in our study were of serotype 11A (n = 9): 5 isolates of ST-9875, 2 of ST-8279, and 1 each of ST-10300 and ST-99. An XDR ST-8279 (serotype 13) clone described in 2014 ([@R2]) was closely related to the 9 serotype 11A isolates in our study. ST-8279 is a double-locus (*aroE* and *xpt*) variant of ST-156, which is closely related to global clone Spain9V-3 ([@R2]). Spain9V-3 is related to 3 ST-3642 isolates (serotype 11A) reported in Taiwan in 2010 ([@R11]) and to 3 MDR ST-166 isolates (serotype 11A) reported in South Korea in 2013 ([@R12]). In our study, 3 novel STs of MDR *S. pneumoniae* were identified (ST-9875, ST-9876, and ST-10300). All the ST-8279, ST-9875, and ST-10300 isolates in our study were serotype 11A, with the exception of 1 of the ST-8279 isolates. The ST-9875 and ST-10300 isolates were single-locus variants (in the *spi* and *gki* genes, respectively) of ST-8279. ST-9876 is a 1-locus (*aroE*) variant of an ST-3384 (serotype 9V) clone registered in the PubMLST database.

Serotypes 19F and 23F are included in the 13-valent pneumococcal conjugated vaccine (PCV13), but serotype 11A is not included in PCV13. Serotype 11A is, however, included in the 23-valent pneumococcal polysaccharide vaccine (PPSV23). The US CDC currently recommends the PPSV23 for all adults [\>]{.ul}65 years of age and all persons 2--64 years of age who are at high risk for pneumococcal disease ([@R13]). Through national vaccine programs in South Korea, since 2013, PPSV23 has been provided to all adults [\>]{.ul}65 years of age, and since 2014, 10-valent pneumococcal conjugated vaccine or PCV13 have been provided to young children free of charge ([@R14]).

Conclusions
===========

In South Korea, serotype 11A was the most predominant serotype of the 16 levofloxacin-resistant and XDR *S. pneumoniae* isolates we found. Seven levofloxacin-resistant *S. pneumoniae* strains were isolated in 2014 alone; the dominant serotype was again 11A (n = 5). All except 1 of these 7 serotype 11A isolates were resistant to the 9 different antimicrobial agents tested. We identified 3 novel STs of MDR serotype 11A *S. pneumoniae* in our study. *S. pneumoniae* serotype 11A isolates with novel STs require careful monitoring to combat the increasing prevalence and diversification of MDR pneumococcal strains, especially those with resistance to fluoroquinolones, β-lactams, and third-generation cephalosporins.
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